Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 2/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.42 |
| ▸ | PYGL | P06737 | 2/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | PYGM | P11217 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599303 | 1.00 | RHEB (0.50) | RHEBGRIN1UTS2RPYGLS1PR2 | |
| SCHEMBL3599300 | 1.00 | RHEB (0.50) | RHEBGRIN1UTS2RPYGLS1PR2 | |
| SCHEMBL3607487 | 0.93 | RHEB (0.47) | RHEBGRIN1GHSR | |
| SCHEMBL3610445 | 0.93 | RHEB (0.47) | RHEBGRIN1GHSR | |
| SCHEMBL3607484 | 0.93 | RHEB (0.47) | RHEBGRIN1GHSR | |
| SCHEMBL3595113 | 0.91 | GRIN1 (0.52) | RHEBGRIN1PYGLS1PR2SMYD3 | |
| SCHEMBL3603093 | 0.85 | HRH4 (0.57) | RHEBUTS2RPYGLPYGMGHSR | |
| SCHEMBL3598903 | 0.85 | HRH4 (0.57) | RHEBUTS2RPYGLPYGMGHSR | |
| SCHEMBL3598901 | 0.85 | HRH4 (0.57) | RHEBUTS2RPYGLPYGMGHSR | |
| SCHEMBL20536134 | 0.84 | RHEB (0.62) | RHEBPYGLSMYD3ROCK2GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2009158375-A1 | AZA-CYLIC INDOLE- 2 -CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | RHEB 2282/4885GRIN1 650/4885UTS2R 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.